Abstract
87TiP Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have